Aardvark Therapeutics Operating Income 2023-2025 | AARD

Aardvark Therapeutics operating income from 2023 to 2025. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

Aardvark Therapeutics Operating Income 2023-2025 | AARD

Aardvark Therapeutics operating income from 2023 to 2025. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$209.6B
Amgen (AMGN)$149.1B
Gilead Sciences (GILD)$130.2B
Vertex Pharmaceuticals (VRTX)$125.6B
Bristol Myers Squibb (BMY)$100.2B
CSL (CSLLY)$74.3B
GSK (GSK)$74.1B
Regeneron Pharmaceuticals (REGN)$61.6B
Argenex SE (ARGX)$36.2B
Alnylam Pharmaceuticals (ALNY)$30.5B
BioNTech SE (BNTX)$23.7B
BeiGene (ONC)$22.8B
Biogen (BIIB)$17.4B
Genmab (GMAB)$13.3B
Genmab (GNMSF)$13.3B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.3B
Illumina (ILMN)$11.3B
Incyte (INCY)$11.3B
Ascendis Pharma (ASND)$10.1B
Exelixis (EXEL)$10B
Swedish Orphan Biovitrum (BIOVF)$9.6B
Moderna (MRNA)$9.6B
QIAGEN (QGEN)$9B
Exact Sciences (EXAS)$7.7B
Bio-Techne Corp (TECH)$7.6B
Repligen (RGEN)$7.3B
Halozyme Therapeutics (HALO)$7.3B
Roivant Sciences (ROIV)$7.2B
Revolution Medicines (RVMD)$6.8B